Alnylam Pharmaceuticals Inc (ALNY)
$224.47 -$2.81 (-1.24%) 1:55 PM 10/23/2026
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$31.02B -
Day's Range
$222.00 - $229.39 -
Volume
1,319,892 -
52 Week Low / High
$197.81 - $495.55 -
PE Ratio
39.09x -
PEG Ratio
0.32 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Analyst ratings: Buy 23, Hold 7, Sell 0.
Company News
-
US Stock Market Today: S&P 500 Futures Steady On Strong Jobs And PMI Focus — Oct 23, 2026
The Morning Bull - US Market Morning Update Friday, Oct, 23 2026 US stocks look set for a cautiously positive open, with S&P 500 futures hovering slightly higher. The single driver this morning is labor strength, as fresh jobless claims signal a still resilient employment backdrop. Initial...
-
- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice yearly dosing - - Unique targeting approach reduces both mutant huntingtin...
-
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? — Oct 22, 2026
Alnylam Pharmaceuticals (ALNY) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results c...
-
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? — Oct 20, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on RNA interference, a technique that switches off the genes behind certain diseases. At about $31 billion, the stock features on our list of 9 New Contenders for the S&P 500 Index. It stands out as a rare large b...
Portfolio
Comprised of 1 portfolios



